Expert Discusses Immunotherapy Advancements in a Rapidly Changing GU Field – Targeted Oncology
Targeted Oncology |
Expert Discusses Immunotherapy Advancements in a Rapidly Changing GU Field
Targeted Oncology PD-L1 expression is used as a marker [for immunotherapy] in lung cancer, but it is not used as a significant marker in GU malignancies. Now, we do see that patients with urothelial carcinoma who have PD-L1–positive tumors do respond better. Also, in … |
